Most translational science efforts
focus on integrating the work of academic and industry scientists, and they
leave out a critical set of participants: patients. This is problematic because
the speed and quality of the feedback between the bench and the bedside is a
critical rate-limiting factor for medical progress.
Getting to the point
The virtue of patients
Kotz, J. SciBX 5(25);
Published online June 21, 2012
on a Framework for Developing a New Taxonomy of Disease. Toward precision medicine: building a knowledge
network for biomedical research and a new taxonomy of disease.
A. BioCentury 19(32), A9-A10; Aug. 1, 2011
R.S. et al. Amyotroph. Lateral Scler. 11, 502-507 (2010)
COMPANIES AND INSTITUTIONS MENTIONED
AstraZeneca plc (LSE:AZN; NYSE:AZN), London,
Cystic Fibrosis Foundation, Bethesda, Md.
Genentech Inc., South San Francisco, Calif.
Kaiser Permanente, Oakland, Calif.
Medco Health Solutions Inc. (NYSE:MHS), Franklin Lakes, N.J.
Multiple Myeloma Research Foundation, Norwalk, Conn.
National Academy of Sciences, Washington, D.C.
PatientsLikeMe, Cambridge, Mass.
Pfizer Inc. (NYSE:PFE), New York, N.Y.
Roche (SIX:ROG; OTCGX:RHHBY), Basel, Switzerland
Sage Bionetworks, Seattle, Wash.
Sanofi (Euronext:SAN; NYSE:SNY), Paris, France
Scripps Health, San Diego, Calif.
Scripps Translational Science Institute, La Jolla, Calif.
University of California, San Francisco, Calif.
Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), Cambridge, Mass.
WellPoint Inc. (NYSE:WLP), Indianapolis, Ind.